Please login to the form below

Not currently logged in
Email:
Password:

ViiV Healthcare

This page shows the latest ViiV Healthcare news and features for those working in and with pharma, biotech and healthcare.

Gilead’s Biktarvy gets European approval, setting up battle with GSK

Gilead’s Biktarvy gets European approval, setting up battle with GSK

Juluca, marketed by GSK-led ViiV Healthcare is a two-drug combination which received EU approval just last month, putting the companies into direct competition.

Latest news

  • GSK’s vaccines president Debruyne heads for the exit GSK’s vaccines president Debruyne heads for the exit

    GSK’s vaccines outlet grew by 6% last year, a significant amount compared to its pharma and consumer healthcare businesses, which saw growths of 3% and 2% respectively. ... along with vaccines chairman Moncef Slaoui and ViiV Healthcare’s - GSK’s HIV

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    ViiV’ s two-drug HIV combo backed by CHMP. The committee also backs two biosimilar medicines. ... ViiV Healthcare’s dual HIV therapy Juluca has been given a green light by the EMA’s Committee for Medicinal Products for Human Use (CHMP), setting up

  • Gilead says switching studies back new HIV therapy Biktarvy Gilead says switching studies back new HIV therapy Biktarvy

    share for ViiV, so Gilead will have to pull out all the stops to build momentum behind its new drug. ... GSK alleges that Gilead’s HIV integrase inhibitor bictegravir infringes on patents held by ViiV on dolutegravir, and it wants to receive royalties

  • Gilead’s triple HIV drug approval prompts GSK lawsuit Gilead’s triple HIV drug approval prompts GSK lawsuit

    Gilead’ s triple HIV drug approval prompts GSK lawsuit. ViiV claims bictegravir infringes its patent estate. ... GSK’s ViiV Healthcare unit has filed a lawsuit against Gilead claiming that its integrase inhibitor bictegravir - which is one of the

  • ViiV starts trial of HIV-preventing injections for women ViiV starts trial of HIV-preventing injections for women

    ViiV Healthcare’s injectable HIV drug cabotegravir could provide a new way for women to protect themselves from HIV, for example if their partner refuses to wear a condom. ... to protect themselves from HIV, ”commented ViiV ’s chief scientific and

More from news
Approximately 21 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    The first is the revised deal between ViiV Healthcare (the speciality HIV company formed by GSK and Pfizer in 2009) and Shionogi. ... Under the new agreement, ViiV Healthcare will acquire the exclusive global rights to the assets in the Shionogi-ViiV

  • Shionogi: an expanding commercial focus Shionogi: an expanding commercial focus

    The candidate the company is most excited about is the nce-daily HIV integrase inhibitor dolutegravir, which Shionogi is co-developing with the Pfizer and GlaxoSmithKline's ViiV Healthcare venture. ... Establishes Shionogi-GlaxoSmithKline joint venture

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet

    GlaxoSmithKline has promoted Deborah Waterhouse to replace ViiV Healthcare's CEO Dominique Limet when he steps down from the HIV-focused firm at the end of March. ... He said: “ Establishing and then leading ViiV Healthcare for the past seven years has

  • Phil Golz appointed commercial director at HealthUnlocked Phil Golz appointed commercial director at HealthUnlocked

    Phil Golz appointed commercial director at HealthUnlocked. Moves from ViiV Healthcare to join the socialnetwork for health. ... He joins the company from ViiV Healthcare, where he was executive director, and prior to that he served as head of commercial

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics